NCT07697079Not yet recruiting
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer: A Prospective Study
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
This prospective cohort study aims to construct an artificial intelligence (AI)-derived predictive model for neoadjuvant chemotherapy response prediction in patients with locally advanced gastric cancer based on preoperative ultrasound (US), computed tomography (CT) images and liquid biopsy. Additionally, we explore the potential biological mechanisms behind this model.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 5 Jul 2026
- Start date
- Feb 2027
- Primary completion date
- Dec 2029
- Lead sponsor
- Liu Yang
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07697079
What you commit to
- Study type: Observational
- Planned participants: 300
- From Feb 2027 to the primary completion date, Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Discontinued chemotherapy, modified treatment regimen, or lack of complete postoperative pathological assessment.
- Unavailable follow-up data precluding evaluation of chemotherapy response.
- Concurrent participation in another clinical trial; or any other conditions judged by investigators to warrant subject withdrawal, including severe comorbidities requiring simultaneous treatment (psychiatric disorders included), alcohol dependence, substance abuse, or familial/social factors that may compromise subject safety or treatment compliance.
Other illness
- Diagnosis of non-primary gastric cancer.
- Incomplete imaging data, failure to collect peripheral blood samples, or substandard sample quality.
Who the study is looking for
- Capable of understanding the study and voluntarily signing the written informed consent form (ICF) prior to any study-specified research procedures.
- Aged ≥18 and ≤80 years old at the time of ICF signing.
- Pathologically confirmed locally advanced gastric cancer (LAGC, cT2NxM0-cT4NxM0) with clinical indications for neoadjuvant chemotherapy.
- Completion of gastrointestinal contrast-enhanced ultrasound and contrast-enhanced abdominal CT before neoadjuvant chemotherapy.
- Provision of peripheral blood samples before chemotherapy (for genetic and protein detection).
- Availability of postoperative pathological specimens for TRG grading after standardized neoadjuvant chemotherapy.
- Willing and able to comply with all study protocol requirements.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| QianfoshanH Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.